UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-41925 CG Oncology, Inc. (Exact Name of Registrant as Specified in its Charter) De ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Delaware 001-41925 37-1611499 (State or Other Jurisdiction of Incorporation)(Commission File Number) (IRS Employer Identification No.) 400 Spectrum Center Drive Suite 2040 Irvine, California 92618 (Address of Principal Executive Offices) (Zip Code) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share CGON The Nasdaq Global Select Market FORM 8-K CURRENT REPORT Pursuant ...

wildpixel Fresh from its large, $380mn IPO in January, CG Oncology (NASDAQ:CGON) achieved high success after its bladder cancer molecule cretostimogene grenadenorepvec demonstrated a 75.2% complete response at any time in 105 patients. The study was a phase 3 monotherapy study in NMIBC or high-risk non-muscle invasive bladder cancer that's unresponsive to Bacillus Calmette Guerin. This data, presented on May 3, was quickly followed on May 24 by data from a phase 2 study of the same molecule, this time in co ...

– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature Medicine and featured at ASCO 2024 – – Announced 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint in the CORE-001 study – – Demonstrated 75.2% CR rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in Cretostimogene Monothe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Securities registered pursuant to Section 12(b) of the Act: FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ | --- | --- | |--------------------------------------- ...

Financial Results Announcement - CG Oncology, Inc. announced its financial results for the quarter ended June 30, 2024 [6] - The press release detailing the financial results was issued on August 8, 2024 [6] - The press release is attached as Exhibit 99.1 and incorporated by reference [6] Regulatory and Compliance Information - The information in the Form 8-K, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act [7] - The report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 [5] - The report was signed by Josh Patterson, General Counsel and Chief Compliance Officer of CG Oncology, Inc. [10] Company Classification and Market Information - CG Oncology, Inc. is classified as an emerging growth company [6] - CG Oncology, Inc. is registered on the Nasdaq Global Select Market under the trading symbol CGON [4] Company Contact Information - The company's principal executive offices are located at 400 Spectrum Center Drive, Suite 2040, Irvine, California 92618 [2] - The company's telephone number is (949) 409-3700 [5]

th 11 elect E i = ad pl 101 Com 01 11 -1 F Ti A LEAST Property TE p nt 1 lar ----------- i P in The Property action t r H 2017 th n 1000 Phone 34 and live y ckly E in wildpixel Maybe different isn't always better, but it can be just as good. CG Oncology (NASDAQ:CGON) is different from the biotechs I normally prefer to look at, as the company doesn't really have a platform or a pipeline beyond its lead candidate cretostimogene grenadenorepvec, an oncolytic adenovirus targeted at non-muscle invasive bladder c ...

Date of report (Date of earliest event reported) May 9, 2024 CG Oncology, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (Exact Name of Registrant as Specified in Charter) Delaware 001-41925 37-1611499 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 400 Spectrum Center Drive, Suite 2040 Irvine, CA 92618 (949) 409-3700 (Address an ...

WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-41925 CG Oncology, Inc. (Exact Name of Registrant as Specified in its Charter) Delawa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____________________ TO _____________________ Commission File Number 001-41925 CG Oncology, Inc. (Exact name of registrant as specified in its Charter) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR (State or ...